Director at 4D Molecular Therapeutics (NASDAQ: FDMT) receives 50,000 options

Rhea-AI Filing Summary

4D Molecular Therapeutics director Jacob Chacko received a new stock option grant covering 50,000 shares of common stock. The option has an exercise price of $9.42 per share and expires on June 16, 2036. It was granted automatically under the company’s non-employee director compensation program.

The option vests as to one-third of the shares on June 17, 2027, then in equal monthly installments until fully vested on June 17, 2029, contingent on his continued service. The award will also vest in full upon a Change in Control as defined in the 2020 Incentive Award Plan. Following this grant, he holds options for 50,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chacko Jacob

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	50,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. Automatically granted pursuant to the terms of the Company's non-employee director compensation program. The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Key Figures

Stock options granted: 50,000 options Exercise price: $9.42 per share Expiration date: June 16, 2036 +2 more

5 metrics

Stock options granted 50,000 options Director grant reported on Form 4

Exercise price $9.42 per share Strike price of stock option grant

Expiration date June 16, 2036 Option term end date

Initial vesting date June 17, 2027 One-third of options vest

Full vesting date June 17, 2029 Options fully vested if service continues

Key Terms

non-employee director compensation program, stock option, Change in Control, 2020 Incentive Award Plan, +1 more

5 terms

non-employee director compensation program financial

"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."

stock option financial

"The stock option vests and becomes exercisable with respect to 1/3 of the total shares..."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Change in Control financial

"Additionally, the stock options will vest in full upon the consummation of a Change in Control..."

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

2020 Incentive Award Plan financial

"Change in Control (as defined in the 2020 Incentive Award Plan)."

vests and becomes exercisable financial

"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027..."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chacko Jacob

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.42	06/17/2026		A(1)		50,000		(2)	06/16/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

2. The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

	/s/ Scott Bizily as Attorney-in-Fact for Jacob Chacko	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did FDMT director Jacob Chacko report in this Form 4 filing?

He reported receiving a stock option grant for 50,000 shares of 4D Molecular Therapeutics common stock. The award is part of the non-employee director compensation program and gives him the right to buy shares at a fixed exercise price.

What is the exercise price of Jacob Chacko’s new FDMT stock options?

The options have an exercise price of $9.42 per share. This is the price he must pay to purchase each share if he exercises the options after they have vested and before they expire.

How do Jacob Chacko’s FDMT stock options vest over time?

One-third of the 50,000 options vest on June 17, 2027. The remaining options vest in equal monthly installments until full vesting on June 17, 2029, assuming he continues serving as a director throughout the vesting period.

When do Jacob Chacko’s FDMT stock options expire?

The options expire on June 16, 2036, if they are not exercised earlier. After this expiration date, any unexercised options will no longer be valid and cannot be used to purchase company shares.

What happens to Jacob Chacko’s FDMT options if there is a Change in Control?

The options will vest in full upon the consummation of a Change in Control, as defined in the company’s 2020 Incentive Award Plan. This means any remaining unvested options become fully exercisable if such a transaction occurs.

How many FDMT options does Jacob Chacko hold after this grant?

After this transaction, he holds options to acquire 50,000 shares of 4D Molecular Therapeutics common stock directly. This Form 4 only reports this specific grant and the resulting derivative holdings from it.